Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13551 - 13575 of 15142 in total
Investigational
Investigational
Investigational
GIVI-MPC is a therapy that uses human-induced pluripotent stem cell-derived myogenic progenitor cells.
Investigational
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Investigational
ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.
Investigational
Investigational
Investigational
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
Investigational
Investigational
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
Matched Description: … Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and
PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.
Investigational
Investigational
Investigational
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
Displaying drugs 13551 - 13575 of 15142 in total